A downtrend has been apparent in Veru Inc. (VERU) lately. While the stock has lost 5.2% over the past week, it could witness ...

A downtrend has been apparent in Veru Inc. (VERU) lately with too much selling pressure. The stock has declined 9.2% over the ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Oatly Group AB (OTLY) 161.49% +5.22, Energy ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation ...

Veru has transitioned into a late clinical-stage biopharmaceutical company, concentrating on cardiometabolic and inflammatory diseases. CEO Mitchell Steiner highlighted enobosarm and sabizabulin ...

Veru Inc (NASDAQ:VERU) is set to release its Q1 2025 earnings on Feb 13, 2025.The consensus estimate for Q1 2025 revenue is $3.02 million, and the earnings are expected to come in at -$0.07 per share ...

The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts ...

VERU has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Veru in a research note on Thursday, January 2nd ...

$VERU insiders have traded $VERU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a ...

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation, pharmacokinetic ...